leadf
logo-loader
viewImmuPharma PLC

ImmuPharma says US partner makes regulatory and operational progress ahead of phase III trial of lupus drug

The group said the US Food & Drug Administration has agreed to accept a submission made by Avion Pharmaceuticals supporting a request for a Type-A meeting

ImmuPharma PLC -

ImmuPharma PLC (LON:IMM) said its licensing partner has made headway with the regulatory authorities in the US ahead of a new optimised phase III study of the former’s lupus treatment.

It said the US Food & Drug Administration (FDA) has agreed to accept a submission made by Avion Pharmaceuticals supporting a request for a Type-A meeting that would provide clinical guidance for a phase III trial of the ImmuPharma-developed drug Lupuzor.

The information for the Type A meeting was forwarded to the FDA on November 6, 2020, and, normally, a meeting would take place within 30 days. However, this cannot be guaranteed, ImmuPharma said.

In the same announcement, the company said Avion had asked the FDA to consider the conditional approval of Lupuzor ahead of the completion of the final-stage clinical study.

This would be based on the “clinically significant data” generated from completed phase II and III trials. These showed the treatment was extremely safe and well-tolerated.

Finally, ImmuPharma said production of a new batch of Lupuzor had begun specifically for the phase III trial.

Quick facts: ImmuPharma PLC

Price: 11.68465 GBX

AIM:IMM
Market: AIM
Market Cap: £29.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmuPharma’s partner Avion set to meet FDA in December to discuss Phase 3...

Dr Tim Franklin, Chief Operating Officer of ImmuPharma PLC (LON:IMM) joins Proactive London's Katie Pilbeam to discuss ImmuPharma's announcement that The US Food & Drug Administration (“FDA”) has confirmed 4th December 2020 will be the date for the Type ‘A’ Meeting Request, with Avion...

on 25/11/20

2 min read